IFNG and Alzheimer disease: The decision of choosing IFNγ to stimulate CHME3 microglia was supported by the involvement of this cytokine in AD pathology, reported in both mild- and severe-stage patients compared to individuals with mild cognitive impairment (MCI) (Belkhelfa et al., 2014).